Biomarker-based treatment option for preschool children with recurrent wheeze

Biomarker-based treatment option for preschool children with recurrent wheeze - Biomarker-based treatment for preschool wheeze

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008335

Enrollment

Registered

2012-07-03

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

budesonide inhalation suspension montelukast

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recurrent wheeze more than 3 occasions (one should be confirmed by a physician) Improvement of wheeze by inhaled/oral short-acting beta2 agonisit Wheezing episodes within 2 weeks before enrollment Wheezing episodes during run-in period Positive specific IgE to house dust mite Serum EDN>53ng/ml

Exclusion criteria

Exclusion criteria: patients who have been treated with any asthma controller before enrollment

Design outcomes

Primary

Measure	Time frame
Asthma Control Days	—

Secondary

Measure	Time frame
asthma exacerbation	—

Countries

Japan

Contacts

Public ContactMizuho Nagao

Mie National Hospital Institute for Clinical Research

mizuhonagao@mie-m.hosp.go.jp059-232-2531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026